REPORT – ERYTECH’S COMBINED SHAREHOLDERS’ MEETING ON JUNE 24, 2022
ERYTECH Pharma announced that its Annual General Meeting was held on Friday, June 24, 2022.
ERYTECH Pharma announced that its Annual General Meeting was held on Friday, June 24, 2022.
ERYTECH’s shareholders are hereby informed of the Annual General Meeting which will be held on June 24, 2022 at 09:00am CEST at the Hôtel Intercontinental Paris – Le Grand, 2…
ERYTECH Pharma announced that its CEO, Gil Beyen, will present at the H.C. Wainwright Global Investment Conference. The conference will be held in a hybrid format from May 23-26, 2022,…
ERYTECH Pharma provided a business and financial update at the end of March 2022.
ERYTECH Pharma announced that it had filed its 2021 Universal Registration Document for the year ended December 31, 2021, including the management report and the annual financial report with the…
ERYTECH Pharma announced the sale of its U.S. manufacturing facility to Catalent, a leading contract development and manufacturing organization (CDMO) in advanced therapies.
The study confirms the potential of eryaspase (GRASPA®) as an attractive treatment option for acute lymphoblastic leukemia (ALL) patients with hypersensitivity to PEG-asparaginase
ERYTECH Pharma announced the presentation of its novel red blood cell vesiculation technology at the 24th Meeting of the European Red Cell Society (ERCS), taking place from April 7 to…
ERYTECH Pharma today announced their participation in upcoming investor conferences and invites investors to participate in one-on-one meetings.
ERYTECH Pharma (Nasdaq & Euronext: ERYP) provided a business update and an update on its cash position at the end of December 2021.